Submit an abstract to the AACR IO 2025, February 23-26, 2025, in Los Angeles. This new major conference will encompass the very best of basic, translational, and clinical research in immunology, inflammation and immunotherapies for cancer, including immuno-oncology (IO) drugs, inflammatory modulators, vaccines, and cellular therapies.
The FDA has granted priority review to sunvozertinib for advanced/metastatic NSCLC with EGFR exon 20 insertion mutations after progression on chemotherapy.
Combining aerobic and resistance-based physical activity with dexamethasone may improve quality of life and reduce the effects of fatigue.
To join a team for the 2025 SurgOnc Bowl, please complete the following questionnaire. For more information and the rules of engagement, please visit this…
The determination of unbiased cancer risk estimates in hereditary breast and ovarian cancer syndrome (HBOC) poses several challenges. The article by Katona and colleagues is…
Stem cell transplant programs at the Dana-Farber Brigham Cancer Center received outstanding reviews from the CIBMTR.
Amer Zeidan, MBBS, MHS, Yale University and Yale Cancer Center, New Haven, CT, discusses his key myelodysplastic syndrome (MDS) highlights from this year’s ASH meeting.…
During a Community Case Forum event in partnership with the Medical Oncology Association of Southern California, Edward S. Kim, MD, MBA, discussed the FLAURA2 and…
RP1 with nivolumab elicited an ORR of 38.7% with an acceptable safety profile in patients with advanced melanoma who progressed on anti–PD-1 therapy.
New research indicates that adding immunotherapy to muscle-invasive bladder cancer treatment can improve event-free and overall survival.
SAN ANTONIO — The addition of anthracyclines to adjuvant taxane-based chemotherapy improved survival for certain high-risk patients with breast cancer, according to data presented at…
